151 related articles for article (PubMed ID: 3092373)
1. [Usefulness of 2-mercaptoethanol sodium sulfonate (Mesnum) in the prevention of hemorrhagic cystitis in patients undergoing bone marrow transplantation].
Grañena A; Gardella S; Marín P; Carreras E; Montserrat E; Rozman C
Sangre (Barc); 1986; 31(3):307-10. PubMed ID: 3092373
[No Abstract] [Full Text] [Related]
2. Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia.
Blacklock H; Ball L; Knight C; Schey S; Prentice G
Cancer Treat Rev; 1983 Sep; 10 Suppl A():45-52. PubMed ID: 6414695
[No Abstract] [Full Text] [Related]
3. Mesna versus forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplant patients (preliminary data).
Hows J; Mehta A; Gordon-Smith EC
Cancer Treat Rev; 1983 Sep; 10 Suppl A():53-6. PubMed ID: 6414696
[No Abstract] [Full Text] [Related]
4. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
Hows JM; Mehta A; Ward L; Woods K; Perez R; Gordon MY; Gordon-Smith EC
Br J Cancer; 1984 Dec; 50(6):753-6. PubMed ID: 6437430
[TBL] [Abstract][Full Text] [Related]
5. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
Ehrlich RM; Freedman A; Goldsobel AB; Stiehm ER
J Urol; 1984 May; 131(5):960-2. PubMed ID: 6423841
[TBL] [Abstract][Full Text] [Related]
6. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
Shepherd JD; Pringle LE; Barnett MJ; Klingemann HG; Reece DE; Phillips GL
J Clin Oncol; 1991 Nov; 9(11):2016-20. PubMed ID: 1941060
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation.
Link H; Neef V; Niethammer D; Wilms K
Blut; 1981 Nov; 43(5):329-30. PubMed ID: 6799018
[No Abstract] [Full Text] [Related]
8. Bone marrow transplantation for Wiskott-Aldrich syndrome: report of 2 cases with use of 2-mercaptoethane sulfonate.
Goldsobel AB; Ehrlich RM; Mendoza GR; Stiehm ER
Transplantation; 1985 May; 39(5):568-70. PubMed ID: 3922097
[No Abstract] [Full Text] [Related]
9. Mesnum and cyclophosphamide cystitis.
Lancet; 1980 Nov; 2(8205):1195. PubMed ID: 6107795
[No Abstract] [Full Text] [Related]
10. [Evaluation of the benefits of sodium 2-mercaptoethane sulfonate (MESNA) therapy for children undergoing high-dose chemotherapy].
Sato J; Takaue Y; Saito S; Okamoto Y; Hirao A; Shimizu T; Abe T; Watanabe T; Kawano Y; Ninomiya T
Rinsho Ketsueki; 1993 Jan; 34(1):7-12. PubMed ID: 8450612
[TBL] [Abstract][Full Text] [Related]
11. A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients.
Khojasteh NH; Zakerinia M; Ramzi M; Haghshenas M
Transplant Proc; 2000 May; 32(3):596. PubMed ID: 10812128
[No Abstract] [Full Text] [Related]
12. [Prevention of urotoxic complications during therapy with cytostatics. The problem of the interaction between sodium-II-mercaptoethanesulfonate and cyclophosphamide].
Possinger K; Ehrhart H; Misera C; Hartenstein R
Fortschr Med; 1981 Oct; 99(40):1650-2. PubMed ID: 6795099
[No Abstract] [Full Text] [Related]
13. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
[TBL] [Abstract][Full Text] [Related]
14. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
Scheef W; Klein HO; Brock N; Burkert H; Günther U; Hoefer-Janker H; Mitrenga D; Schnitker J; Voigtmann R
Cancer Treat Rep; 1979 Mar; 63(3):501-5. PubMed ID: 106965
[TBL] [Abstract][Full Text] [Related]
15. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Marti C; Steiner R; Viollier AF
Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
[TBL] [Abstract][Full Text] [Related]
16. Hemorrhagic cystitis after conditioning for bone marrow transplantation and its prophylaxis.
Moriyama Y; Koike T; Shibata A
Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():531-6. PubMed ID: 6441037
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
18. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
Korkmaz A; Oter S; Deveci S; Goksoy C; Bilgic H
J Urol; 2001 Sep; 166(3):1119-23. PubMed ID: 11490309
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study.
Freedman A; Ehrlich RM; Ljung BM
J Urol; 1984 Sep; 132(3):580-2. PubMed ID: 6433044
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of hemorrhagic cystitis due to cyclophosphamide for conditioning of bone marrow transplantation].
Mori T; Harada M; Yoshida T; Ohotake S; Shiobara S; Matsue K; Odaka K; Kondo K; Nakao S; Ueda M
Rinsho Ketsueki; 1984 Apr; 25(4):528-34. PubMed ID: 6381790
[No Abstract] [Full Text] [Related]
[Next] [New Search]
